|04/26/17||The Medicines Company Reports First-Quarter 2017 Financial Results|
|PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 26, 2017--
The Medicines Company (NASDAQ:MDCO) today announced its business and
financial results for the first-quarter ended March 31, 2017.
“During the first quarter of 2017, The Medicine Company continued to
deliver excellent execution against our 2017 objectives, significantly
advancing key development programs, strictly managing cash deployment to
enhance our ability to support our products and pipelin... |
|04/26/17||The Medicines Company and Alnylam Pharmaceuticals Announce Agreement with FDA on Phase III Clinical Program for Inclisiran|
|— Pivotal trials will enroll approximately 1,500 subjects randomized
to inclisiran versus approximately 1,500 subjects randomized to placebo,
with a primary endpoint of LDL-C and an 18-month study period —
— NDA submission anticipated at or around the end of 2019 —
PARSIPPANY, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 26, 2017--
The Medicines Company (NASDAQ:MDCO) and Alnylam Pharmaceuticals, Inc.
(NASDAQ:ALNY) today announced that T... |
|04/17/17||The Medicines Company to Present Data at ECCMID 2017 on Infectious Disease Portfolio Including Investigational Antibiotic Meropenem-Vaborbactam|
|PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 17, 2017--
Company (NASDAQ:MDCO) today announced that data from its portfolio
of antimicrobial products and late-stage product candidates will be
featured in presentations at the 27th Annual European
Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2017)
to be held April 22-25, 2017, in Vienna, Austria.
The Company will present data on its investigational antibiotic,
|04/12/17||The Medicines Company to Announce First-Quarter 2017 Financial Results on April 26, 2017|
|PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 12, 2017--
Company (NASDAQ:MDCO) will host a conference call on Wednesday,
April 26, 2017, at 8:30 a.m., Eastern Daylight Time, to discuss
first-quarter 2017 financial results and operational developments.
The dial-in information to access the call is listed below:
U.S./Canada: (877) 359-9508
International: (224) 357-2393
A taped replay of... |